Severity and organ distribution of graft‐versus‐host disease with post‐transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA‐matched or single‐allele mismatched stem cell transplantation
- 18 August 2024
- journal article
- research article
- Published by Wiley in European Journal of Haematology
- Vol. 113 (6) , 776-787
Abstract
Objective: This retrospective single center study aims to describe changes in the severity and organ‐specific distribution of GvHD, by comparing the outcomes of 3 distinct GvHD prophylaxis approaches.Methods: Between January 2012 and June 2022, 226 patients underwent allogeneic hematopoietic stem cell transplantation from HLA‐matched or 1‐allele mismatched related or unrelated donors. Fifty‐eight (26%) received prophylaxis with calcineurin inhibitor in combination with mycophenolate mofetil or a short course of methotrexate (Cohort‐1), 87 (38%) tacrolimus plus sirolimus (Cohort‐2), and 81 (36%) post‐transplant cyclophosphamide (PTCy) plus tacrolimus (Cohort‐3).Results: The incidence of grade II‐IV aGvHD was 69% vs. 41.4% vs. 27.2%; p < .01. The most significant reduction with PTCy was observed in both stage 3–4 skin and lower gastrointestinal (GI) involvement (p < .01). The incidence of moderate‐to‐severe cGvHD at 12 months was 34.5% vs. 34.5% vs. 6.2%; p < .01. Moderate‐to‐severe skin and GI cGvHD was less common after PTCy (p < .01). The 1‐year GvHD‐free/relapse‐free survival was higher with PTCy (p < .01).Conclusions: Our study indicates that PTCy‐based GvHD prophylaxis reduces the frequency and severity of both acute and chronic GvHD, with a notable decrease in severe GI and cutaneous manifestations. The higher GRFS may result in lower GvHD‐related mortality, leading to an improved quality of life among survivors.Keywords
Funding Information
- Instituto de Salud Carlos III (RD16/0011/0028)
This publication has 36 references indexed in Scilit:
- Post-transplant cyclophosphamide versus antithymocyte globulin in allogeneic hematopoietic cell transplantation: a meta-analysisAnnals of Hematology, 2021
- ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant SurvivorsTransplantation and Cellular Therapy, 2018
- Current indication for hematopoietic cell transplantation in adultsHematology/Oncology and Stem Cell Therapy, 2017
- Factors Predicting Graft-versus-Host Disease–Free, Relapse-Free Survival after Allogeneic Hematopoietic Cell Transplantation: Multivariable Analysis from a Single CenterTransplantation and Cellular Therapy, 2016
- International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International ConsortiumTransplantation and Cellular Therapy, 2016
- National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group ReportTransplantation and Cellular Therapy, 2015
- Successful Prevention of Acute Graft-versus-Host Disease Using Low-Dose Antithymocyte Globulin after Mismatched, Unrelated, Hematopoietic Stem Cell Transplantation for Acute Myelogenous LeukemiaTransplantation and Cellular Therapy, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Tacrolimus and Mycophenolate Mofetil after Nonmyeloablative Matched-Sibling Donor Allogeneic Stem-Cell Transplantations Conditioned with Fludarabine and Low-Dose Total Body IrradiationTransplantation and Cellular Therapy, 2006
- Reduced-Intensity Conditioning Allogeneic Blood Stem Cell Transplantation with Fludarabine and Oral Busulfan with or without Pharmacokinetically Targeted Busulfan Dosing in Patients with Myeloid Leukemia Ineligible for Conventional ConditioningTransplantation and Cellular Therapy, 2005